Tempus AI Inc - Company Profile
Powered by 
All the sales intelligence you need on Tempus AI Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Tempus AI Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Tempus AI Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Tempus AI Inc (Tempus) is a technology company that develops artificial intelligence-enabled precision medicine solutions for healthcare providers and life sciences organizations. The company's diagnostic products include NGS diagnostics, PCR profiling, and other anatomic and molecular pathology testing. Its platforms include Hub, Lens, Next, Pixel, Assays, Algos, and olivia. The company also offers OneOme pharmacogenomics testing solutions, CDx and lab services, clinical research operations, clinical trial recruitment, and care gap intelligence services. Tempus also offers xR IVD, an RNA next-generation sequencing-based in vitro diagnostic device for solid malignant neoplasms. The company operates across Asia-Pacific, Africa, America, Europe, the Middle East, North America and South America. Tempus is headquartered in Chicago, Illinois, the US.
Headquarters
United States of America
Address
Suite 510, 600 West Chicago Avenue, Illinois, 60654
Website
www.tempus.com
Telephone
1 833 5144187
No of Employees
3,800
Industry
Technology and Communications
Ticker Symbol & Exchange
TEM (NASD)
Revenue (2024)
$1.3B
83.4%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
65.3%
(2024 vs 2023)
Market Cap*
$9.9B
Net Profit Margin (2024)
XYZ
81.1%
(2024 vs 2023)
* As of and is in US$
Tempus AI Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| xR In Vitro Diagnostic Device | Tempus PRO |
| Tempus Platform | |
| Genomics: | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Acquisitions/Mergers/Takeovers | In August, the company acquired Paige, an AI company, for US$81.25 million. |
| 2025 | Acquisitions/Mergers/Takeovers | In March, the company acquired Deep 6 AI. |
| 2025 | Acquisitions/Mergers/Takeovers | In February, the company acquired Ambry Genetics. |
Competitor Comparison
| Key Parameters | Tempus AI Inc | IQVIA Holdings Inc | Labcorp Holdings Inc | Quest Diagnostics Inc | ICON Plc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | Ireland |
| City | Chicago | Durham | Burlington | Secaucus | Dublin |
| State/Province | Illinois | North Carolina | North Carolina | New Jersey | Dublin |
| No. of Employees | 3,800 | 94,000 | 71,000 | 46,000 | 40,200 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Eric Lefkofsky | Chief Executive Officer; Chairman | Executive Board | 2015 | 56 |
| James Rogers | Chief Financial Officer | Senior Management | 2021 | 40 |
| Shane Woods, PhD | Chief Strategy Officer; General Manager - Data Products | Senior Management | - | - |
| Shane Colley | Chief Technology Officer | Senior Management | - | - |
| Andrew Polovin | Executive Vice President; Secretary; Chief Legal Officer | Senior Management | 2026 | 52 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer